EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant Is On Par With Novo Nordisk’s Famous Wegovy/Ozempic Injectable, Based On Animal Studies – Vivani Medical (NASDAQ: VANI)
Wednesday, Vivani Medical Inc VANI has released preclinical data on the weight loss effects of NPM-115, the company’s semiannual miniature exenatide subcutaneous implant under development for chronic weight management.
In a study with high-fat diet-induced obese mice, NPM-115 produced approximately 20% weight loss compared to a sham implant control after a treatment duration of 28 days.
The company says the weight loss is comparable to that seen in mice treated with Novo Nordisk A/S NGO popular Ozempic/Wegovy (semaglutide) injections in the same study.
Supratherapeutic doses provided for both NPM-115 (single administration delivering exenatide at approximately 530 nmol/kg/day) and semaglutide (weekly injections approximately 2,700 nmol/kg/week) were selected to maximize the weight loss potential of exenatide and semaglutide. semaglutide.
In a second study in healthy rats, a single administration of the exenatide implant NPM-119, under development for type 2 diabetes, resulted in approximately 25% lower body weight than a vehicle implant. control after 15 weeks of treatment with an expected duration of effect of six months.
NPM-119 delivered exenatide at a rate of approximately 320 nmol/kg/day and demonstrated a smooth, non-fluctuating release of exenatide in both cases. in vitro And alive studies.
NPM-119 has previously demonstrated pharmacokinetic data showing continuous and therapeutic exposure levels to exenatide over six months in healthy rats.
Given that NPM-115 is a higher dose version of an otherwise similar product to NPM-119, the durability of the weight effect demonstrated in this study should translate into future studies using NPM-119. 115.
The company also revealed that semaglutide is the active pharmaceutical ingredient in NPM-139, a subcutaneous miniature GLP-1 implant under development for chronic weight management, with the added potential benefit of one-time administration. times a year.
These developments are part of a strategic shift to prioritize the company’s anti-obesity implants.
The weight loss potential of exenatide in humans has not been fully evaluated in currently marketed exenatide products. AstraZeneca Plc AZN Byetta (twice-daily injection) and Bydureon (weekly injection) for type 2 diabetes, potentially due to limitations associated with adherence and dosage.
Read next: Weight-loss drug market crowded as Viking Therapeutics drops encouraging Phase 2 data from obesity study.
Price action: VANI shares are trading up 1.98% at $1.03 premarket at last check Wednesday.
Photo by Vidmir Rais via Pixabay
